Showing 11-20 of 40 results for "".
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- SENTÉ Raises $5 million, Appoints New CEOhttps://practicaldermatology.com/news/sent-raises-5-million-appoints-new-ceo/2458713/There’s big news coming out of SENTÉ this week. Fresh of the announcement that they closed on a $5 million financing round, the company also appointed Laurent Combredet as President and Chief Executive Officer. Mr. Combredet was G
- Mirvaso Now Available in the UKhttps://practicaldermatology.com/news/20140417-mirvaso_now_available_in_the_uk/2459269/Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK. The active ingredient, brimonidine, restricts excessive blood f
- Andrew Weinstein Voted AAD President-Electhttps://practicaldermatology.com/news/Andrew-Weinstein-Voted-AAD-President-Elect/2471798/Andrew H. Weinstein, MD, MPH, FAAD, was voted president-elect of the American Academy of Dermatology (AAD), the organization announced. Dr. Weinstein will be joined by vice president-elect Thomas E. Rohrer, MD, FAAD. Newly elected members of the board of directors are Alina G. Bridges, DO,
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- DISCREET: Apremilast Effective for Genital Psoriasis for Treatment Nonrespondershttps://practicaldermatology.com/news/discreet/2462239/Apremilast was efficacious in reducing the symptoms of genital psoriasis (G-PsO) in patients who didn't respond to topical treatments or who were not adequately controlled by topical therapy, new research indicates. DISCREET aimed to evaluate the efficacy and safety of apremil
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in g